vitamin

Kinetic determination of vitamin B1

...nt to quantify thiamine in a variety of commercial vitamin preparations. 2 The papers by Ryan and Ingle and ...;Bowers students analyzed five types of commercial vitamin tables using a simplified technique: samples were run at room temperature without stirring, the reac...

Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins

...is of Lipid Soluble Vitamins Analysis of vitamin D2 (ergocalciferol) and D3 (cholecalciferol) is cr...h enough for a baseline separation of both vitamin D compounds. On both columns, separation is enhanced at lower temperature (25C). ...

Reforming FDA: Focus on safety, let market judge efficacy

...ithout approval for other uses. FDA monitors the vitamin and nutraceutical markets for safety only, and doe...e market, as it is in the European, off-label, and vitamin world. Some may argue that we need a strong, efficacy-driven FDA, but remember that in 1962 communic...

Cytochroma settles lawsuit with Genzyme

...reat and prevent diseases and disorders related to vitamin D hormone deficiency. The company is deciding whether to open an office in Madison....

Deltanoid Pharmaceuticals begins phase II osteoporosis study

...and it's growing as the population ages. 2MD is a vitamin D compound discovered in the laboratory of Hector ...gan in 2001 to advance the development of patented vitamin D compounds licensed from the Wisconsin Alumni Research Foundation . In addition to osteoporosis, t...

Biotech with Madison ties raises $21M in capital

...oma , a Canadian firm seeking to commercialize new vitamin D products, acquired the Madison-based Proventiv T...D) market, primarily addressing problems caused by vitamin D deficiency in kidney patients. This new financing will allow Cytochroma to achieve key milestones...

Madison life-science firms agree to co-develop kidney product

... products to prevent and treat diseases related to vitamin D deficiency, has offices in Madison and Markham, Ontario, Canada. aOvaTech, founded in Madison in 2001, previously has marketed its product as an alternative strategy for animal nutrition....

Deltanoid presses on with drug research

...as conceived in 1999 and specializes in the use of vitamin D compounds, now has 19 employees. The company's g...al companies. The race is on to find uses for the vitamin D compound, DeLuca said. We think we've found them. Osteoporosis drugs, for instance, have tremendo...

Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO

...base of operations for Cytochroma, and expands its vitamin D product portfolio. It also positions the company...disease (CKD) market, including psoriasis, cancer, vitamin D deficiency, and related disorders. The combined business will have 30 employees and multiple lea...

Immune boosting beverage relying on Milwaukee firm's packaging technology

...aunching Defense Vitamin & Mineral Supplement -- a vitamin and mineral enhanced immune boosting beverage utilizing the FreshCan technology of Degussa FreshTech Beverages in Milwaukee. FreshTech is a patented delivery system developed to contain an air- and water-tight plastic container called the FreshCan...

Genzyme acquistion of Bone Care approved, significant impact forecast

...ompany focused on the development and marketing of vitamin D-based therapies. A panel of Bone Care shareholde...n , was founded in 1987. Its flagship product, the vitamin D hormone Hectorol, was based around the research of Hector DeLuca - currently president and CEO of ...

FTC has fast-tracked Bone Care merger

...us is in nephrology, utilizing Hectorol, a novel vitamin D hormone therapy, to treat secondary hyperparath... chronic kidney disease, the company is developing vitamin D hormone therapies to treat hyperproliferative disorders such as cancer and psoriasis....

Bone Care expands patent protection of core drug offering

...ber of serious diseases, all based on the patented vitamin D complex. Bone Care announced in May that the Massechusetts-based Genzyne Corp. agreed to acquire the company for $600 million in cash, a deal expected to be completed in the third quarter with shareholder approval. Genzyme has still not announced ...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

...s well-positioned to continue gaining share in the vitamin D market as the company has doubled he size of its sales force since last year and the 0.5 mcg Hectorol capsule continues to gain share," First Albany said in an April 27 report. In a conference call Wednesday morning, Genzyme Chairman and CEO Henri...

Tech Digest (11/15/2004)

...consin-Madison spin-off, makes treatments based on vitamin D, including its flagship product, Hectorol, which the FDA approved this April to treat kidney disease. Modine extends contract to develop CO2 coolants Modine Manufacturing Company announced on Thursday that it has a contract the U.S. Army to con...

BoneCare doubles options and profits as fiscal year closes

...pening of new markets for its primary product, the vitamin D hormone Hectorol. Used to treat secondary hyperparathyroidisma condition that causes patients with chronic kidney disease to suffer organ damage and bone lossthe drug has recently been converted to a half-microgram capsule so it can be provided to ...

DeLuca speaks out on entrepreneurialism, tech transfer, and WARF

... in 1971 and 1972 for their work on derivatives of vitamin D3. Those patents are responsible for the money th...ratories and marketed under the name Zemplar uses vitamin D to assist patients facing kidney dialysis and renal failure. "It's currently WARF's best earner,...

Life Sciences: Wisconsin - The Smart Choice Part Two

...emia; Pharmaceuticals based on Hector DeLucas vitamin D derivatives, which have been prescribed worldwid...t bone disorders and other diseases resulting from vitamin D deficiencies; And most recently, James Thomsons isolation of human embryonic stem cells, whic...

UW discovery could lead to new TB treatments

...l. The enzyme, in turn, depends on a derivative of vitamin B2 to make a cell wall building block. The work pu...y Kiessling's group shows that the enzyme uses the vitamin in a new way, which also gives it a new biological role. Detailing the interplay between vitamin B2...

FDA approves Bone Cares Hectorol for treatment of kidney disease

...doxercalciferol) Capsules. Hectorol, a pro-hormone vitamin D2 analog, is currently approved for the treatment...nts inability to produce adequate levels of active vitamin D hormone. As CKD progresses, vitamin D hormone levels decline with SHPT typically characterized by ...

Americas Third Coast nurtures biotechnology

...ational ( www.bonecare.com ) specializes in novel vitamin D therapies for people with chronic kidney disease...ee products on the U.S. market, Hectorol, to treat vitamin D deficiency in patients with chronic kidney disease, says Basil Mundy, vp of corporate development....

Bone Care Names New Chairman

...scovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney (renal) disease, osteoporosis and psoriasis. The Company markets two FDA approved products, Hectorol(R) Injection and Hectorol(R) Capsules for the treatment of seconda...

WTN Interview: Carl Gulbrandsen
WARF - A Unique and Successful Technology Transfer Organization

...sen: We receive the majority of our revenue from vitamin D technology. A number of vitamin D patents have been licensed, but its still just one technology. WTN: What percent of WARFs revenu...